TY - JOUR AU - Almási, Szintia AU - Baráth, Bence AU - Szaszák, Panna AU - Kővári, Bence AU - Sejben, Anita TI - Hypermucinosus és kehelysejtszegény, gyulladásos bélbetegséghez társult, non-conventionalis dysplasia colorectalis adenocarcinoma mellett [Hypermucinous and goblet cell-deficient, IBD-associated, non-conventional dysplasia besides colorectal adenocarcinoma]. [esetismertetés] TS - [esetismertetés] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 164 PY - 2023 IS - 51 SP - 2039 EP - 2044 PG - 6 SN - 0030-6002 DO - 10.1556/650.2023.32946 UR - https://m2.mtmt.hu/api/publication/34565525 ID - 34565525 N1 - Szövegében 3 oldalnál rövidebb esetismertetés, ezért besorolása rövid közlemény az MTA V. Osztályának ajánlása alapján. (SE, SZTE admin5, 2024.02.22.) AB - A gyulladásos bélbetegséggel (IBD) élő betegekben a colorectalis carcinoma kialakulásának esélye az átlagpopulációban észleltek kétszerese. Az invazív daganatokat megelőzően ezekben a betegekben nagyobb a rizikó dysplasia kialakulására is. Az utóbbi években számos, IBD-hez társult, ún. non-conventionalis dysplasia altípust azonosítottak, melyekről a jelenleg is zajló kutatásoknak köszönhetően egyre több információval rendelkezünk. Egy 62 éves, 14 éve relabáló colitis ulcerosával diagnosztizált és kezelt nőbeteg subtotalis colectomiás preparátumában colitis ulcerosa mellett a sigmabélben invazív adenocarcinomát azonosítottunk mucinosus területekkel. A daganat közvetlen környezetében kehelysejtszegény, valamint hypermucinosus IBD-hez társult, non-conventionalis dysplasiát észleltünk, az utóbbinak intestinalis és foveolaris altípusa is elkülöníthető volt. A felhalmozódó ismeretek tükrében az IBD-hez társult, non-conventionalis dysplasiák ismerete több szempontból is fontos lehet a diagnosztikában és a klinikai ellátásban, ugyanis ezek a laesiók makroszkóposan laposak vagy láthatatlanok lehetnek, megnehezítve a dysplasia endoszkópos szűrését. Ismeretük a patológus számára kiemelten fontos, hiszen a reaktív és reparatív folyamatoktól való elkülönítésük sokszor nagy kihívást jelent. Továbbá, a hagyományos típusoknál gyakrabban társultak ’high-grade’ dysplasiával, valamint colorectalis carcinomával. Molekuláris hátterüket tekintve, sokkal gyakrabban észlelhető bennük aneuploidia. Mindezen ismeretek a hagyományos neoplasiákhoz képest rosszabb prognózis rizikót vetítenek elő, és az esetlegesen nehezen azonosítható endoszkópos képüket is figyelembe véve felismerésük után az IBD-s betegek szorosabb utánkövetése és esetleges véletlenszerű biopsziás mintavétel mérlegelendő. Orv Hetil. 2023; 164(51): 2039–2044. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Sárközy, Márta AU - Watzinger, Simon AU - Kovács, Zsuzsanna AU - Acar, Eylem AU - Márványkövi, Fanni AU - Szűcs, Gergő AU - Lauber, Gülsüm Yilmaz AU - Galla, Zsolt AU - Siska, Andrea AU - Földesi, Imre AU - Fintha, Attila AU - Kriston, András AU - Kovács, Ferenc AU - Horváth, Péter AU - Kővári, Bence AU - Cserni, Gábor AU - Krenács, Tibor AU - Szabó, Petra Lujza AU - Szabó, Gábor Tamás AU - Monostori, Péter AU - Zins, Karin AU - Abraham, Dietmar AU - Csont, Tamás Bálint AU - Pokreisz, Peter AU - Podesser, Bruno K. AU - Kiss, Attila TI - Neuregulin-1β Improves Uremic Cardiomyopathy and Renal Dysfunction in Rats JF - JACC:BASIC TO TRANSLATIONAL SCIENCE J2 - JACC-BASIC TRANSL SC VL - 8 PY - 2023 IS - 9 SP - 1160 EP - 1176 PG - 17 SN - 2452-302X DO - 10.1016/j.jacbts.2023.03.003 UR - https://m2.mtmt.hu/api/publication/33941648 ID - 33941648 LA - English DB - MTMT ER - TY - JOUR AU - Pipek, Orsolya Anna AU - Alpár, Donát AU - Rusz, Orsolya AU - Bödör, Csaba AU - Udvarnoki, Zoltán András AU - Medgyes-Horváth, Anna AU - Csabai, István AU - Szállási, Zoltán AU - Madaras, Lilla AU - Kahán, Zsuzsanna AU - Cserni, Gábor AU - Kővári, Bence AU - Kulka, Janina AU - Tőkés, Anna-Mária TI - Genomic Landscape of Normal and Breast Cancer Tissues in a Hungarian Pilot Cohort JF - INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES J2 - INT J MOL SCI VL - 24 PY - 2023 IS - 10 PG - 19 SN - 1661-6596 DO - 10.3390/ijms24108553 UR - https://m2.mtmt.hu/api/publication/33814839 ID - 33814839 N1 - Funding Agency and Grant Number: NKFIH, Hungary [FK20-134253, K21-137948, TKP2021-EGA-24, TKP2021-NVA-15, NVKP-16-1-2016-0004]; EU's Horizon 2020 research and innovation program [739593]; Janos Bolyai Research Scholarship program of the Hungarian Academy of Sciences [BO/00125/22]; New National Excellence Program of the Ministry for Innovation and Technology [UNKP-22-5-SE-7]; Complementary Research Excellence Program; Kerpel Talent Award of Semmelweis University [EFOP-3.6.3-VEKOP-16-2017-00009]; ELIXIR Hungary Funding text: This study was supported by the following grants: NKFIH, Hungary: FK20-134253, K21-137948, TKP2021-EGA-24, TKP2021-NVA-15 and NVKP-16-1-2016-0004. The study was also supported by the EU's Horizon 2020 research and innovation program (No. 739593), the Janos Bolyai Research Scholarship program (BO/00125/22) of the Hungarian Academy of Sciences, the UNKP-22-5-SE-7 grant of the New National Excellence Program of the Ministry for Innovation and Technology, by the Complementary Research Excellence Program, the Kerpel Talent Award of Semmelweis University (EFOP-3.6.3-VEKOP-16-2017-00009), and the ELIXIR Hungary. AB - A limited number of studies have focused on the mutational landscape of breast cancer in different ethnic populations within Europe and compared the data with other ethnic groups and databases. We performed whole-genome sequencing of 63 samples from 29 Hungarian breast cancer patients. We validated a subset of the identified variants at the DNA level using the Illumina TruSight Oncology (TSO) 500 assay. Canonical breast-cancer-associated genes with pathogenic germline mutations were CHEK2 and ATM. Nearly all the observed germline mutations were as frequent in the Hungarian breast cancer cohort as in independent European populations. The majority of the detected somatic short variants were single-nucleotide polymorphisms (SNPs), and only 8% and 6% of them were deletions or insertions, respectively. The genes most frequently affected by somatic mutations were KMT2C (31%), MUC4 (34%), PIK3CA (18%), and TP53 (34%). Copy number alterations were most common in the NBN, RAD51C, BRIP1, and CDH1 genes. For many samples, the somatic mutational landscape was dominated by mutational processes associated with homologous recombination deficiency (HRD). Our study, as the first breast tumor/normal sequencing study in Hungary, revealed several aspects of the significantly mutated genes and mutational signatures, and some of the copy number variations and somatic fusion events. Multiple signs of HRD were detected, highlighting the value of the comprehensive genomic characterization of breast cancer patient populations. LA - English DB - MTMT ER - TY - JOUR AU - Sejben, Anita AU - Sejben, István AU - Annamária, Budai AU - Gregory, Y. Lauwers AU - Kővári, Bence TI - Inflammatory Bowel Disease-Mimicking Colitis Associated With Nintedanib-Based Therapy in a Lung Cancer Patient JF - INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY J2 - INT J SURG PATHOL VL - 31 PY - 2023 IS - 7 SP - 1326 EP - 1328 PG - 3 SN - 1066-8969 DO - 10.1177/10668969221143472 UR - https://m2.mtmt.hu/api/publication/33539208 ID - 33539208 N1 - Department of Pathology, Faculty of Medicine, Albert Szent-Györgyi Medical School, University of Szeged, Szeged, Hungary Department of Pathology, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary Department of Internal Medicine, Bács-Kiskun County Teaching Hospital, Kecskemét, Hungary Department of Pathology, H. Lee Moffitt Cancer Center and Research Institute and Departments of Pathology and Oncologic Sciences, University of South Florida, Tampa, FL, United States Cited By :1 Export Date: 20 March 2024 CODEN: IJSPF Correspondence Address: Sejben, A.; Department of Pathology, Hungary; email: sejben.anita@gmail.com Chemicals/CAS: atezolizumab, 1380723-44-3; bevacizumab, 216974-75-3, 1438851-35-4; carboplatin, 41575-94-4; cisplatin, 15663-27-1, 26035-31-4, 96081-74-2; docetaxel, 114977-28-5; nintedanib, 928326-83-4, 656247-17-5, 656247-18-6; vinorelbine tartrate, 125317-39-7, 71486-22-1; nintedanib LA - English DB - MTMT ER - TY - JOUR AU - Lerch, Julia M AU - Pai, Rish K AU - Brown, Ian AU - Gill, Anthony J AU - Jain, Dhanpat AU - Kővári, Bence AU - Kushima, Ryoji AU - Sheahan, Kieran AU - Slavik, Tomas AU - Srivastava, Amitabh AU - Lauwers, Gregory Y AU - Langner, Cord TI - Interobserver agreement of estimating the extent of intestinal metaplasia in patients with chronic atrophic gastritis JF - VIRCHOWS ARCHIV J2 - VIRCHOWS ARCH VL - 480 PY - 2022 IS - 6 SP - 1277 EP - 1281 PG - 5 SN - 0945-6317 DO - 10.1007/s00428-021-03245-9 UR - https://m2.mtmt.hu/api/publication/33202311 ID - 33202311 AB - The extent of gastric intestinal metaplasia (GIM) can be used to determine the risk of gastric cancer. Eleven international gastrointestinal expert pathologists estimated the extent of GIM on haematoxylin and eosin (H&E)- and Alcian blue-Periodic acid Schiff (AB-PAS)-stained slides of 46 antrum biopsies in 5% increments. Interobserver agreement was tested with the intraclass correlation coefficient (ICC). Correlation between standard deviation and extent of GIM was evaluated with the Spearman correlation. The interobserver agreement was very good (ICC = 0.983, 95% confidence interval (CI) 0.975-0.990). The use of AB-PAS did not increase the agreement (ICC = 0.975, 95% CI 0.961-0.985). Cases with a higher amount of metaplastic epithelium demonstrated a higher standard deviation (rs = 0.644; p < 0.01), suggesting lower diagnostic accuracy in cases with extensive GIM. In conclusion, estimating the extent of GIM on H&E-stained slides in patients with chronic atrophic gastritis can be achieved satisfactorily with high interobserver agreement, at least among international expert gastrointestinal pathologists. LA - English DB - MTMT ER - TY - JOUR AU - Varelas, Ana I AU - Kővári, Bence AU - Bruckner, Elisabeth AU - Lauwers, Gregory Y AU - Langner, Cord TI - Metachronous double-hit by transarterial chemoembolisation (TACE) with fotemustine inducing dysplasia-like atypia in the gallbladder and stomach-A diagnostic pitfall JF - HISTOPATHOLOGY J2 - HISTOPATHOLOGY VL - 81 PY - 2022 IS - 1 SP - 128 EP - 130 PG - 3 SN - 0309-0167 DO - 10.1111/his.14653 UR - https://m2.mtmt.hu/api/publication/33202308 ID - 33202308 LA - English DB - MTMT ER - TY - JOUR AU - Kim, Dae Won AU - Kim, Young-Chul AU - Kővári, Bence AU - Chung, Vincent AU - Alese, Olatunji B AU - El-Rayes, Bassel F AU - Li, Daneng AU - Park, Wungki AU - Kim, Richard D TI - Biomarker analysis from a phase II multi-institutional study of nivolumab in patients with advanced refractory biliary tract cancer JF - European journal of cancer (Oxford, England : 1990) J2 - Eur J Cancer VL - 176 PY - 2022 SP - 171 EP - 180 PG - 10 SN - 1879-0852 DO - 10.1016/j.ejca.2022.09.014 UR - https://m2.mtmt.hu/api/publication/33202305 ID - 33202305 AB - Our previous phase II study demonstrated that nivolumab provides modest but durable clinical efficacy in patients with refractory biliary tract cancer, suggesting the significant clinical benefit of nivolumab in selected patients and the necessity of predictive biomarkers. We evaluated clinicopathological characteristics and tumour microenvironment of the patients who were enrolled the trial to identify potential biomarkers.Baseline clinicopathological characteristics and pretreatment tumour samples were collected. The obtained tumour samples were assessed for whole exome sequencing, RNA sequencing and immunohistochemistry. Their correlations with clinical outcome were analysed.Pretreatment tumour evaluation revealed PD-L1 expression on tumour, CD8 T cell infiltration and high ratio of CD8 T cell/regulatory T cell in tumour microenvironment were significantly associated with prolonged progression-free survival (PFS), while PD-1 expression on lymphocytes and CD68 macrophages infiltration in tumour microenvironment had no predictive role. Asian patients (N = 3) had improved PFS and disease control rate compared with non-Asian (N = 54). A six-gene predictive model was constructed by evaluation of total 23,550 candidate genes from RNA sequencing of baseline tumour samples using LASSO-Cox regression analysis, and high score of the six-gene prediction model was associated with prolonged PFS.This study suggests that PD-L1 expression on tumour, CD8 T cell infiltration and high ratio of CD8/regulatory T cells and six-gene expression profile in tumour microenvironment may be potential predictive biomarkers of nivolumab in biliary tract cancers. Further studies are needed to confirm these findings. LA - English DB - MTMT ER - TY - JOUR AU - Kim, Richard D. AU - Kővári, Bence AU - Martinez, Maria AU - Xie, Hao AU - Sahin, Ibrahim H. AU - Mehta, Rutika AU - Strosberg, Jonathan AU - Imanirad, Iman AU - Ghayouri, Masoumeh AU - Kim, Young-chul AU - Kim, Dae Won TI - A phase I/Ib study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer JF - EUROPEAN JOURNAL OF CANCER J2 - EUR J CANCER VL - 169 PY - 2022 SP - 93 EP - 102 PG - 10 SN - 0959-8049 DO - 10.1016/j.ejca.2022.03.026 UR - https://m2.mtmt.hu/api/publication/32955612 ID - 32955612 AB - Aim: In contrast to mismatch repair deficient (dMMR) colorectal cancer (CRC), mismatch repair proficient (pMMR) CRC is usually unresponsive to anti-PD-1 immunotherapy. Recent preclinical data suggest that regorafenib may enhance the antitumor activity of anti-PD-1 immunotherapy. However, the safety and efficacy of regorafenib plus nivolumab have not been established in patients with refractory metastatic pMMR CRC. This study aimed to evaluate the safety and efficacy of regorafenib plus nivolumab in metastatic pMMRMethod: This was a phase I/Ib study with standard 3 + 3 design plus dose expansion of the maximum tolerated dose (MTD) in patients with refractory metastatic pMMR CRC. Patients were treated with regorafenib combined with nivolumab. The primary end-points were doselimiting toxicity (DLT) and MTD. The secondary end-points were objective response rate, safety and overall survival (OS).Results: A total of 52 patients were enrolled, and 51 patients received at least one dose of treatment. Three patients experienced DLT (all grade 3 rash). MTD was regorafenib 80 mg and nivolumab 240 mg every 2 weeks. Most common grade 3/4 treatment-related adverse events were hypertension (16%), rash (10%) and anaemia (6%). Among 40 evaluable patients, stable disease, and disease control rate was 63%. The median progression-free survival and OS were 4.3 and 11.1 months, respectively.Conclusions: Regorafenib plus nivolumab appears to be well tolerated with limited anticancer activity in metastatic pMMR CRC. Trial Registration: ClinicalTrials.gov identifier: NCT03712943. 2022 Elsevier Ltd. All rights reserved. LA - English DB - MTMT ER - TY - JOUR AU - Lerch, Julia M. AU - Pai, Rish K. AU - Brown, Ian AU - Gill, Anthony J. AU - Jain, Dhanpat AU - Kővári, Bence AU - Kushima, Ryoji AU - Sheahan, Kieran AU - Slavik, Tomas AU - Srivastava, Amitabh AU - Lauwers, Gregory Y. AU - Langner, Cord TI - Subtyping intestinal metaplasia in patients with chronic atrophic gastritis: an interobserver variability study JF - PATHOLOGY J2 - PATHOLOGY VL - 54 PY - 2022 IS - 3 SP - 262 EP - 268 PG - 7 SN - 0031-3025 DO - 10.1016/j.pathol.2021.12.288 UR - https://m2.mtmt.hu/api/publication/32710978 ID - 32710978 LA - English DB - MTMT ER - TY - JOUR AU - Tóth, Erzsébet Melinda AU - Sárközy, Márta AU - Szűcs, Gergő AU - Dukay, Brigitta AU - Hajdu, Petra AU - Zvara, Ágnes AU - Puskás, László AU - Szebeni, Gábor AU - Ruppert, Zsófia AU - Csonka, Csaba AU - Kovács, Ferenc AU - Kriston, András AU - Horváth, Péter AU - Kővári, Bence AU - Cserni, Gábor AU - Csont, Tamás Bálint AU - Sántha, Miklós TI - Exercise training worsens cardiac performance in males but does not change ejection fraction and improves hypertrophy in females in a mouse model of metabolic syndrome JF - BIOLOGY OF SEX DIFFERENCES J2 - BIOL SEX DIFFER VL - 13 PY - 2022 IS - 1 PG - 20 SN - 2042-6410 DO - 10.1186/s13293-022-00414-6 UR - https://m2.mtmt.hu/api/publication/32637299 ID - 32637299 N1 - Laboratory of Animal Genetics and Molecular Neurobiology, Institute of Biochemistry, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, Szeged, 6726, Hungary MEDICS Research Group, Department of Biochemistry, University of Szeged Albert Szent-Györgyi Medical School, Dóm tér 9, Szeged, 6720, Hungary Interdisciplinary Center of Excellence, University of Szeged, Dugonics tér 13, Szeged, 6720, Hungary Laboratory of Functional Genomics, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, Szeged, 6726, Hungary Doctoral School in Biology, University of Szeged, Szeged, Hungary Synthetic and Systems Biology Unit, Institute of Biochemistry, Biological Research Centre, Eötvös Loránd Research Network, Temesvári krt. 62, Szeged, 6726, Hungary Single-Cell Technologies Ltd, Temesvári krt. 62, Szeged, 6726, Hungary Institute for Molecular Medicine Finland (FIMM), University of Helsinki, Helsinki, 00014, Finland Department of Pathology, Albert Szent-Györgyi Medical School, University of Szeged, Állomás utca 1, Szeged, LA - English DB - MTMT ER -